American Journal of Kidney Diseases
Volume 51, Issue 2 , Pages 224-232 , February 2008

Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis

  • Waldemar E. Wysokinski, MD

      Affiliations

    • Division of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, MN
    • Division of Hematology, Mayo Clinic and Foundation, Rochester, MN
    • ,
  • Izabela Gosk-Bierska, MD

      Affiliations

    • Department and Clinic of Angiology, Diabetology, and Hypertension, University Medical School of Wroclaw, Wroclaw, Poland
    • ,
  • Eddie L. Greene, MD

      Affiliations

    • Division of Nephrology and Hypertension, Mayo Clinic and Foundation, Rochester, MN
    • ,
  • Diane Grill, MS

      Affiliations

    • Division of Biostatistics, Mayo Clinic and Foundation, Rochester, MN
    • ,
  • Heather Wiste, MS

      Affiliations

    • Division of Biostatistics, Mayo Clinic and Foundation, Rochester, MN
    • ,
  • Robert D. McBane II, MD

      Affiliations

    • Division of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, MN
    • Division of Hematology, Mayo Clinic and Foundation, Rochester, MN
    • Corresponding Author InformationAddress correspondence to Robert D. McBane II, MD, Division of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, 200 SW First St, Rochester, MN 55905.

Received 19 April 2007 ,Accepted 5 October 2007.

References 

  1. Rosenmann E, Pollak VE, Pirani CL. Renal vein thrombosis in the adult: A clinical and pathologic study based on renal biopsies. Medicine. 1968;47:269–335
  2. Duncan RE, Evans AT, Martin LW. Natural history and treatment of renal vein thrombosis in children. J Pediatr Surg. 1977;12:639–645
  3. Zucchelli P. Renal vein thrombosis. Nephrol Dial Transplant. 1992;7(suppl 1):S105–S108
  4. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: Acute and chronic. Am J Med. 1980;69:819–827
  5. Laville M, Aguilera D, Maillet PJ, et al. The prognosis of renal-vein thrombosis (A re-evaluation of 27 cases). Nephrol Dial Transplant. 1988;3:247–256
  6. McCarthy LJ, Titus JL, Daugherty GW. Bilateral renal vein thrombosis and the nephrotic syndrome in adults. Ann Intern Med. 1963;58:837–849
  7. Kanfer A, Fleinknetch D, Broyer M, et al. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diathes Haemorrh. 1970;24:562–568
  8. Thompson C, Forbes CD, Prentice CRM, et al. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med. 1974;43:399–412
  9. Thaler E, Blazar E, Kopsa H, et al. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Hemostasis. 1978;7:257–262
  10. Vigano-D’Angelo S, D’Angelo A, Kauffman CE, et al. Protein S deficiency occurs in the nephrotic syndrome. Am Inter Med. 1987;107:42–51
  11. Sturgill BC, Rowe CT. Renal vein thrombosis and the nephrotic syndrome (Immunofluorescence studies). Arch Intern Med. 1967;120:708–711
  12. Trew PA, Biava CG, Jacobs RP, Hopper J. Renal vein thrombosis in membranous glomerulonephropathy: Incidence and association. Medicine. 1978;57:69–82
  13. Briefel GR, Manis T, Gordon DH. Recurrent renal vein thrombosis consequent to membranous nephropathy. Clin Nephrol. 1978;10:32–39
  14. Llach R. Nephrotic syndrome: Hypercoagulability, renal vein thrombosis, and other thromboembolic complications. In:  Brenner B,  Stein J editor. Contemporary Issues in Nephrology. vol 9:New York, NY: Churchill-Livingston; 1982;p. 121–144
  15. Belman AB, Susmano DF, Burden JJ, et al. Nonoperative treatment of unilateral renal vein thrombosis in the newborn. JAMA. 1970;211:1165–1168
  16. Zigman A, Yazbeck S, Emil S, Nguyen L. Renal vein thrombosis: A 10-year review. J Pediatr Surg. 2000;35:1540–1542
  17. Seeler RA, Kapadia P, Moncado R. Nonsurgical management of thrombosis of bilateral renal veins and inferior vena cava in a newborn infant. Clin Pediatr. 1970;9:543–547
  18. Therneau T, Sicks J, Bergstralh E, Offord J. Expected Survival Based on Hazard Rates. Technical Report Series No. 52 Rochester, MN: Section of Biostatistics, Mayo Clinic; 1994;
  19. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study. Arch Intern Med. 1999;159:445–453
  20. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med. 1998;158:585–593
  21. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med. 2000;160:761–768
  22. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res. 2006;118:397–407
  23. Vaziri ND, Paule P, Toohey J, et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med. 1984;144:1802–1803
  24. Toulon P, Gandrille S, Remy P, Chadeuf G, Jouvin MH, Aiach M. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome. Nephron. 1992;60:176–180
  25. Lau SO, Tkachuck JY, Hasegawa DK, Edson JR. Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. J Pediatr. 1980;96:390–392
  26. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):S401–S428
  27. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393–398
  28. Kearon C, Ginsberg J, Kovacs M, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–639
  29. Ridker PM, Goldhaber SZ, Danielson E, et al. PREVENT Investigators Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–1434
  30. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345:165–169

 Originally published online as doi:10.1053/j.ajkd.2007.10.030 on December 18, 2007.

PII: S0272-6386(07)01393-5

doi: 10.1053/j.ajkd.2007.10.030

American Journal of Kidney Diseases
Volume 51, Issue 2 , Pages 224-232 , February 2008

Article Tools

* Image Usage & Resolution